Friday, February 25, 2011

Sangamo shoots up ahead of HIV data

Tiny Sangamo BioSciences Inc's potential “functional cure” for HIV is getting big attention in advance of a major AIDS scientific meeting.
The 90-employee Richmond company (NASDAQ: SGMO), best known for its zinc finger technology that mediates genes, said its cell therapy, called SB-728, targets a patient’s own CCR5 gene by removing, essentially, the doorknob that HIV turns to gain access to infection-fighting white blood cells.

No comments:

Post a Comment